A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer

A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer.
A novel chemotherapy anaesthetize made from a Davy Jones's locker sponge extended the lives of women with metastatic breast cancer by about 2,5 months, researchers report. The encouraging finding on the drug, known as eribulin, was presented Sunday at the annual assembly of the American Society of Clinical Oncology in Chicago. "We have a major need for fresh therapies," noted study author Dr Christopher Twelves. "We see a statistically significant promote in overall survival in a situation where we rarely see this sort of improvement".

So "Eribulin targets the mechanisms by which the cells divide, which is novel from previous agents," explained Twelves, who is a professor of clinical cancer pharmacology and oncology and make a beeline for of the Clinical Cancer Research Groups at the Leeds Institute of Molecular Medicine and St James' Institute of Oncology in Leeds, UK. More than 750 women were randomized to come into either eribulin or a "treatment of physician's choice," the persist because there isn't a standard care for this type of cancer. In almost all cases, it was another chemotherapy.

The study included women who had already been treated extensively for their cancer, with the norm patient already having undergone four chemotherapies. The researchers blast a 23 percent improvement in median survival when women took eribulin, with the median survival for those in the eribulin heap at just over 13 months vs 10,7 months in the treatment-of -choice group. "These results potentially substantiate eribulin as a new and effective treatment for women with heavily pretreated bosom cancer," said Twelves, who disclosed financial ties with Eisai, which makes eribulin.

Also featured at the intersection Sunday, Italian researchers report that liver biopsies can expose whether a breast cancer that has spread through the body has changed its cellular characteristics, such as estrogen-receptor status, progesterone-receptor significance or HER2 status. These tumor properties often dictate the type of treatment a woman receives, intention that some women may benefit from switching therapy if the characteristics of their cancer change.

Mammography Should Be Done On Time

Mammography Should Be Done On Time.
Breast cancer patients who have mammograms every 12 to 18 months have less endanger of lymph node involvement than those who hiatus longer, therefore improving their outlook, according to an prehistoric new study. As breast cancer progresses, cancer cells may vastness to the lymph nodes and other parts of the body, requiring more extensive treatment. "We found doing mammograms at intervals longer than one and a half years essentially does fake patient prognosis," said examine researcher Dr Lilian Wang.

And "In our study, those patients were found to have a significantly greater lymph node positivity". From 2007 to 2010, Wang evaluated more than 300 women, all of whom were diagnosed with bust cancer found during a boring mammogram. She divided them into three groups, based on the meantime between mammograms: less than one and a half years, one and a half to three years or more than three years.

Most women were in the blue ribbon category. Wang looked to see how many women had cancer that had spread to their lymph nodes. Although nearly 9 percent of those in the shortest time had lymph node involvement, 21 percent of those in the medial group and more than 15 percent in the longest-interval group did. The stage at which the cancer was diagnosed did not different among the groups, she found.

Although the study found an association between more frequent screenings and less lymph node involvement amidst breast cancer patients, it did not establish a cause-and-effect relationship. Wang, an aid professor of radiology at Northwestern University's Feinberg School of Medicine, is scheduled to present the findings Wednesday at the annual rendezvous of the Radiological Society of North America, in Chicago. The best void between routine mammograms has been a point of discussion and debate for years.

Lymphedema Does Not Appear Because Of The Strength Exercises After The Removal Of Breast Cancer

Lymphedema Does Not Appear Because Of The Strength Exercises After The Removal Of Breast Cancer.
Contrary to common wisdom, lifting weights doesn't cause bust cancer survivors to bare the painful, arm-swelling condition known as lymphedema, green research suggests. There's a hint that weight-lifting might even help prevent lymphedema, but more on is needed to say that for sure, the researchers said. Breast cancer-related lymphedema is caused by an increase of lymph fluid after surgical removal of the lymph nodes and/or radiation. It is a dour condition that may cause arm swelling, awkwardness and discomfort.

And "Lymphedema is something women at the end of the day fear after breast cancer, and the guidance has been not to lift anything heavier even than a purse," said Kathryn H Schmitz, steer author of the study to be presented Wednesday at the San Antonio Breast Cancer Symposium. "But to effect women to not use that affected arm without giving them a prescription for a personal valet is an absurdist principle," she added.

A former study done by the same team of researchers found that exercise actually stabilized symptoms to each women who already had lymphedema. "We really wanted to put the last stamp on this to say, 'Hey, it is not only proper but may actually be good for their arms," said Schmitz, who is an associate professor of forebears medicine and community health at the University of Pennsylvania School of Medicine and a member of the Abramson Cancer Center in Philadelphia.

And "It's almost similarly to a paradigm shift," said Lee Jones, meticulous director of the Duke Cancer Institute's Center for Cancer Survivorship in Durham, NC "Low-volume rebelliousness training does not exacerbate lymphedema". To see if a slowly progressive rehabilitation program using weights would aid the arm, 134 breast cancer survivors with at least two lymph nodes removed but no cartouche of lymphedema who had been diagnosed one to five years before entry in the study were randomly selected to participate in one of two groups.